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chapter seven
Purchasing to promote
population health
Martin McKee and Helmut Brand
Introduction
While there may still be considerable controversy about how to measure them,
there is a growing consensus that the goals of health systems include improve-
ment in population health, responsiveness to legitimate public expectations,
and fairness of financing (World Health Organization, 2000). This chapter
examines the first of these goals, improvement in population health, and the
contribution that strategic purchasing of health care can make to achieve it.
At the outset it is necessary to recognize, as previous chapters have indicated,
that the concept of strategic purchasing to improve health is still far from the
agenda of health policy makers in many countries. The two limbs of the triple
agency relationship, linking purchasers with public and providers, are often
well established, especially in countries with funding through social insurance,
but the role of purchasers in these relationships has largely been confined to
acting as a means of collecting, pooling and paying the funds required to
provide health care (Busse et al., 2002). The question of what that health
care should consist of has largely been defined by a combination of aggregate
popular demand (in other words, the sum of thousands of individual decisions
to seek care) and opinions of health care providers about what to offer and to
whom. Traditionally, purchasers may have taken a view on the total amount
that they spend, or on the general boundaries of the package that they fund,
such as what is considered health and what social care, or what is considered
mainstream and what alternative care, but with a few exceptions they have been
content to take a passive role.
This is not entirely surprising. Until the twentieth century, health care could
offer little apart from a place of sanctuary. The risk of infection made surgery an
intervention of last choice (Porter, 1997). Consequently, many of the organiza-
tions that we now consider as potential purchasers of care would, at that time,
have placed a much greater priority on their other tasks such as the provision of
financial support for the afflicted and their families. Clearly this situation has
now changed beyond recognition. Modern health care can cure many previ-
ously fatal disorders and, where cure is impossible, allow those with chronic
diseases to lead a normal life (McKee, 1999a). For example, the discovery of
insulin transformed juvenile-onset diabetes from an acute, rapidly fatal disease
of childhood into a chronic, lifelong disorder affecting many body systems
whose management requires the integrated skills of a broad range of specialists.
With diabetes, as with many chronic diseases, the issue of integration is crucial,
as can be seen from the much worse outcomes in the fragmented American
health care system compared with the more integrated models in some
European countries (Leggetter et al., 2002).
Advances in health care account for about half of the improvement in life
expectancy in Western Europe in the past three decades (Mackenbach et al.,
1988), but these advances have not benefited everyone to the same extent.
There are still many people who die unnecessarily, either from conditions that
are treatable or from the adverse effects of treatment. Although less easy to
identify, it seems likely that there are also many people with non-fatal disease
who are being treated inappropriately so that the benefits they achieve from
treatment are less than optimal. Importantly, these differences are not random.
Wherever it has been looked for, death from causes that are preventable with
timely and effective health care is more common among the poor and among
marginalized populations (Marshall et al., 1993). In the next section we examine
why this is so, and what implications it holds for strategic purchasing.
Need or demand?
The traditional model of health care provision, based on a principal–agent
relationship between the public and providers, with purchasers simply acting as
financial intermediaries, is based on the concept that providers should respond
to demand for health care, voiced by individual members of the public and their
families.
But what happens when those in need are unable to express their need as
demand? Traditionally there are two areas where this has been an issue, and, in
both, governments have felt it necessary to put in place alternative arrangements.
These are communicable disease and mental health. Leaving aside any spirit of
altruism (Dowie, 1985), in both cases society has an interest in ensuring that
those in need are treated (or if treatment is not possible, then confined). In the
first case this is because of the risk of contagion. In the second it is the risk to the
orderly conduct of society. Yet in both cases there will be people in need of care
who are either unable or unwilling to demand it. Indeed, they may demand not to
be treated. Consequently, health care systems have traditionally created separate
systems to deal with these issues, often in adjacent facilities, such as the large
fever and psychiatric hospitals on the outskirts of many European cities (Lomax,
1994; Freeman, 1995). These facilities often have had, and in some cases still
have, separate funding streams. Where mainstream care has been funded from
social insurance, local or central government has typically paid for such facilities.
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There are many other situations in which individuals are unable effectively to
express their need for health care as demand. In some cases they will be unaware
of their need. This is especially true in relation to screening programmes. Simply
making a service available does not ensure that it is taken up. Indeed, it may
widen health inequalities as those in most need are often least likely to use it as
they face a variety of real and perceived barriers. This is especially likely with
cervical cancer, which is more common among the poor but who are least
likely to use screening services, even when provided free at point of use (Gillam,
1991). However, it is also true for many other conditions that individuals may
have difficulty distinguishing from the normal ageing process (Sarkisian et al.,
2001). Again this is often socially patterned, with the least well off least likely to
seek help. In other cases they will recognize their need but be unable to express
it as demand. This is especially likely among those from minority populations
(Shaukat et al., 1993; Stronks et al., 2001), and especially illegal migrants, but it
is also true of many other groups whose marginalization is less but is still pres-
ent, such as the disabled. Yet even when need can be expressed as demand it
does not necessarily mean that the demand will be met.
A second question is whether health care providers respond to need. There
are many factors that motivate health professionals to provide services. One is
financial, but this is not the only factor. Health care is more likely to be provided
if it is interesting and involves interactions that are perceived as emotionally
rewarding by the provider. As the technical challenges increase, so the willing-
ness to spend time on the routine diminishes. It is therefore unsurprising that
waiting times for established procedures tend to be greater than for those
introduced more recently (Pope et al., 1991). Similarly, all else being equal, there
is likely to be a reluctance to work in settings that are perceived as especially
difficult, such as deprived inner city areas.
Furthermore, even if need is met, it cannot be assumed that it is met in the
most appropriate way. The relationship between the patient and the health
professional is characterized by asymmetry of information. The patient is cer-
tainly able to judge the quality of many non-clinical aspects of care, but he or
she is disadvantaged in relation to many clinical matters. Clearly, the growth in
access to information via the Internet can redress this imbalance to some extent,
at least in relation to choice of treatment, but it does little to ensure that those
providing treatment have adequate knowledge and skills and are using them
effectively. It also does little to ensure that full opportunity is being taken to go
beyond meeting the immediate need of the individual patient during an
episode of illness, in particular to anticipate their future needs by means of
health promotion.
Thus, a major justification for strategic purchasing is that the traditional
principal–agent relationship between the public and providers fails. Specifically,
in addition to the widely recognized asymmetry of information between
citizens and providers, there is also an asymmetry of information between
providers and purchasers. Each has information not available to the other. The
providers have additional knowledge of the patients seeking their help. The
purchasers have knowledge of the broader population, including those who do
not seek help. The next section explores this issue in more detail, focusing on
the propensity of providers to respond to expressed demand for care.
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The implications for purchasing
The issues raised in the preceding paragraphs effectively determine a framework
for action by organizations that are engaged in strategic purchasing and seek to
enhance the health of their populations. This framework is cyclical, reflecting
the standard model used widely in quality assurance within provider organiza-
tions, where the goal is also to ensure that optimal care is provided (Figure 7.1).
Ideally they would engage in a series of linked activities, each embedded
within an overall strategy to improve health. The first step is to assess health
needs, and in particular those that are less likely to be voiced as demand. The
second is to determine how those needs might best be met, drawing on evidence
of effectiveness, not just in relation to individual interventions but also in
relation to organizational structures and configurations that are most likely
to deliver effective care. The third is to purchase care that complies with this
specification, employing the model of contracting appropriate for their situ-
ation. The fourth is to monitor the impact of this process, seeking to ensure that
effective care is now in place. Finally, as health needs are continually changing,
the assessment of health needs would be revisited.
The reality is, inevitably, far from the ideal. Each of the steps involves com-
plex and often difficult processes. These will be examined below. However, it is
necessary to emphasize that this stylized model rests on one fundamental
assumption. This is that the purchasing of health care is taking place as part of
an agreed strategy, in which the key stakeholders in the health system (and
beyond it) have signed up to programmes that have clearly defined objectives to
improve health. Thus, health strategies are one manifestation of the third limb
of the triple agency relationship underpinning this book. It might be expected
that such strategies would be common, given that all countries have signed up
to initiatives such as the WHO ‘Health 21’ strategy and, before that, to ‘Health for
All (HFA) by the Year 2000’ (WHO Regional Office for Europe, 1985). But what
has happened in practice? The next section reviews the current state of health
strategies within Europe.
Health strategies
One of the most extensive sources of information on national health strategies
in Europe is that looking at the use of health targets conducted by Van Herten
and Van de Water. It reflects the situation in 1998 (Van Herten & Van de Water,
Figure 7.1 Schematic overview of the purchasing process.
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2000), although the situation in individual countries with strategies has been
updated in a subsequent publication in 2002 (Marinker, 2002). While many
countries have a written policy document promoting health, most ‘express the
desirable rather than the actual situation’. Most policies are inspirational
rather than managerial or technical tools to achieve change, indicated by the
relative paucity of quantitative health targets or specification of ways to
achieve them.
A national health policy produced by Sweden, in 2000, illustrates the
inspirational nature of many targets, which in this case included ‘strong solidar-
ity and communal spirit’, ‘good working conditions’, ‘safe sex’ and ‘improved
health orientation in health care’ (Örtendahl, 2002). Yet the situation is chan-
ging, in part as a consequence of the active exchange of experiences within
Europe. Several countries, and regions within countries, have recently gone
beyond the inspirational to develop quantitative health targets. In 1998, Italy
published a national health plan containing five priority areas with 100 targets.
Many were still inspirational, such as to ‘improve quality of life’, but others
defined the extent of change aimed at, such as reducing mortality from heart
disease and stroke by at least 10% (France, 2002). In 2001, Finland adopted a new
intersectoral health programme, building on its earlier ones. It had previously
rejected the concept of health targets, citing its experience in the 1980s when
targets had failed to stimulate effective action. This time, drawing on a careful
analysis of successes and failures elsewhere, it has included eight main targets,
such as a decrease in accidental and violent deaths of one-third among young
adult men, by 2015 (Koskinen & Melkas, 2002). Also in 2001, Ireland adopted a
detailed health strategy encompassing a wide range of issues, with clearly
defined targets linked to timescales and designation of responsibilities for action
(Department of Health and Children, 2001).
Yet the impact of many of these strategies has been disappointing, for several
reasons. Few have achieved a sense of ownership among key stakeholders.
Krasnik has noted how an attempt to develop a health strategy in Denmark
elicited the response from the medical profession that ‘health for all should be
left to Africans and to nurses’ (Krasnik, 2000). The Italian strategy has been
weakened by the inability to engage the regions, which are increasingly import-
ant players in the health sector. In some countries, such as Spain, progress
towards agreed health strategies has been complicated by political changes
(Alvarez Dardet, 2002). Yet there are exceptions, although these have often
emerged at subnational level.
Since 1991 the regional health department in Catalonia has published a series
of health plans, developed through a process of wide consultation and dis-
seminated extensively among key stakeholders. These have fed into a further
consultative process involving health providers and professionals, the pharma-
ceutical industry, and non-governmental organizations that had sought to gen-
erate a consensus on effective interventions to meet the needs identified in the
plans (Tresserras et al., 2000). The results were used to develop guidance of
models of care, including strengthening of preventive activities, which were
then incorporated into contracts with providers.
Also in Spain, a strategy developed in the Canary Islands achieved wide public
participation. In Sweden, the county of Östergötland worked closely with
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municipal authorities and professional associations to develop policies based on
widespread consensus and which formed the basis for effective partnerships
(Hansson, 2000). In North-Rhine-Westphalia, initially in the face of the trad-
itional German opposition to an extension of the role of government in the
health care system, a State Health Conference has been established bringing
together a wide range of stakeholders, including the sickness funds, chambers of
physicians and other professions, employers and trade unions (Weihrauch,
2002). This has progressively refined a regional health strategy incorporating
quantitative health targets. Ireland’s health strategy sets broad national targets
but establishes a system by which regional health boards can adapt them to
local circumstances.
Another reason explaining the limited success has been the weak evidence
base on which many strategies are established, both in terms of defining
targets (determining what is achievable but challenging) and establishing
what interventions are likely to be effective in particular circumstances. Again
there are exceptions. For example, each of the Finnish targets is based on a
detailed epidemiological analysis and supported by a series of intermediate
goals and by evidence-based policy guidance on how these might be
achieved.
Often this weak technical base reflects inadequacies in systems of health
monitoring. Recent European Union initiatives have highlighted the many
barriers that exist to assessing the health of the population of Europe. As a
consequence, health strategies in many countries have been accompanied by
measures to enhance health information systems. In the United Kingdom each
of the constituent parts of the country (England, Scotland, Wales and Northern
Ireland) has developed its own strategy, although all are broadly similar. The
earlier English strategy ‘Health of the Nation’ is one of the few to have been
subject to a comprehensive evaluation (Fulop et al., 2000), a process that has
provided important insights into the challenges of implementing a comprehen-
sive health strategy. To set these insights in context it may be helpful to provide
some brief details of what the British strategies involved, using the English
‘Health of the Nation’ strategy as an example.
The strategy was based on five key areas: coronary heart disease and stroke,
cancers, mental health, sexual health and accidents. These were chosen on the
grounds that they were major causes of premature death and disability, effective
policies existed that could reduce them, and measurable targets could be set.
Each key area generated a series of specific, time-defined targets, such as ‘to
reduce the death rate from lung cancer by at least 30% in men and 15% in
women by 2010’. While recognizing that progress required action in many sec-
tors, local health authorities, which were responsible for purchasing health care
as well as for wider public health activities, were designated as the focal point for
coordination and implementation. Action was supported by detailed guidance
on the effectiveness of potential local policies and a regular national health
survey was established to track progress towards achieving the targets. Import-
antly, the evaluation of the strategy found evidence that many elements were
being incorporated into purchasing contracts.
This experience yields important lessons. Strategies should not conflict with
existing systems of accountability. Although England has a well-developed
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system of performance management, at all levels of the National Health Service,
managers were judged on the basis of their ability to meet financial and waiting
list targets rather than those relating to health attainment, which, as a con-
sequence, was often given a low priority. The corollary of this is that perform-
ance can only be achieved if necessary resources are made available. Second,
targets should be credible and should reflect both national and local issues. One
target, a reduction in suicides, was widely criticized because it was far from clear
how it might be achieved. Third, the policies of those involved in delivering the
strategy should be consistent and credible. Commitment to the Health of the
Nation strategy, launched by a Conservative government, was diminished
because of the refusal by government to address, or even to mention, the term
‘health inequalities’, preferring the euphemism ‘health variations’. The sub-
sequent Labour government’s ‘Our Healthier Nation’ strategy was similarly
tarnished by controversy involving a political donation linked to tobacco
advertising.
While these findings are important, a note of caution is required. England  is
among the most centralized of the industrialized countries. In particular, there
is a clear chain of accountability from the Secretary of State (Minister) for Health
to individual physicians that simply does not exist in most other European
countries. Health authorities, as both purchasers of care and bodies accountable
for implementing the health strategy, were uniquely well positioned to bring
the two strands together. This is also the case in Spain, where Catalonia was able
to adopt a similar approach. In contrast, in Germany, North-Rhine-Westphalia
established a new body, bringing together the key stakeholders, to try to achieve
the same goals. The implication is that, where responsibilities for purchasing
care and implementing health strategies are not combined, mechanisms are
needed that will bring them together.
However, the limitations of existing health strategies have important implica-
tions for strategic purchasing. Effective purchasing for health gain requires that
the third limb of the triple agency relationship, between the state and pur-
chasers, should be underpinned by such a strategy. In practice this relationship
is often dominated by concerns about containing costs, as part of the state’s
responsibility to ensure macro-economic stability. Yet in the absence of an
agreed health strategy, regardless of who has developed it, it is difficult to
envisage how strategic purchasing can take place.
Assessing health needs
Health strategies provide a broad framework within which purchasing can
take place, but strategic purchasers must also be informed by the health needs of
the populations for which they are responsible if they are to act effectively on
their behalf. For the reasons stated earlier, need does not simply equate to
demand. It is not sufficient to wait for all those in need of care to turn up at the
door of a health facility. Instead it is necessary to take active steps to assess needs
(Gillam, 1991), defined as the ability to benefit from health care and in particu-
lar where need is least likely to be voiced as demand. It is also important to look
not only where need is not being met, but also where it is inappropriately met,
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for example where individuals are receiving interventions that are inappropriate
for them and so do not gain health benefits. Assessing need is therefore inextric-
ably linked with the issue of clinical effectiveness.
At the very least, information should be obtained, where possible, from the
growing number of national and local health reports (http://www.eva-phr.
nrw.de/), describing patterns of mortality, morbidity and other health-related
measures. For example, successive health plans in Catalonia have been linked
closely to the process of purchasing, as have the new regional health plans in
France. In addition, the French Health Ministry has begun to produce annual
health reports (Haut Comité de la Santé Publique, 2002), which, by highlighting
issues that have otherwise received little attention, are having a gradual impact
on regional strategies.
Perhaps the best known model of needs assessment is that developed by
Stevens and Raftery (Box 7.1), which overlaps with the next section, on specify-
ing care models. This has been used as a framework to bring together the evi-
dence required for comprehensive assessments of need for a large number of
common conditions. The subjects covered include diabetes, coronary heart dis-
ease, stroke, and various cancers, as well as most common surgical procedures.
Health needs assessment is, prima facie, a means of increasing the probability
that the health gain achieved for a given investment of resources will be maxi-
mized. Although the principles of assessing need are now well understood there
is little evidence that purchasers (except in the United Kingdom and in some
parts of Spain) have, to any significant extent, developed explicit mechanisms
that involve links to purchasing.
It is always difficult to say why something does not happen. However, a
few observations concerning the United Kingdom may be pertinent. The
prominence given to needs assessment is a direct consequence of the estab-
lishment of a purchaser–provider split in 1990 when health authorities were
made responsible for the health (and not just the health care) of a defined
population. This degree of responsibility is rare in Europe, especially in sys-
tems with social insurance where there is no geographically defined popula-
tion. The scope to assess need was considerable because of the extensive data
on population health, and in particular on inequalities in health and access
Box 7.1 Framework for assessing need
1. Statement of the context of the problem.
2. Subcategories.
3. Prevalence and incidence.
4. Services available.
5. Effectiveness and cost-effectiveness of services.
6. Models of care.
7. Outcomes and targets.
Source: Stevens & Raftery (1994).
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to health care by social class and ethnicity, as well as data from a virtually
monopolistic provider of care, again a situation that did not apply in many
other countries. Finally, the United Kingdom has a very strong public health
community, with many public health professionals employed in the National
Health Service. It was almost inevitable that they would be called upon to use
their epidemiological skills once the idea of a purchaser–provider split was
conceived.
The corollary is that several of these factors are not present in some
other systems, so even if the intention to develop needs assessment linked to
purchasing exists, it may be more difficult to implement.
Specifying care models
Having assessed the health needs of the population on whose behalf care is
being purchased, the next, and inextricably linked, step is to define the models
of care that should be provided. This activity has its origins in the technology
assessment and evidence-based health care movements. In the 1960s and 1970s
it became clear that the effectiveness of many health interventions had been
inadequately evaluated. Researchers identified numerous examples of variation
in use of interventions that were attributed to uncertainty about the indications
for using them (McPherson et al., 1982). At the same time, the growth in med-
ical technology and concerns about the safety of ever more powerful drugs were
stimulating a reassessment of the ability of existing evaluative and regulatory
regimes to both ensure safety and reduce unnecessary costs.
In part these problems reflected weaknesses in the evidence base on which
decision makers could draw. They also reflected weaknesses in the decision-
making process.
Initiatives such as the Cochrane Collaboration contributed to major
methodological advances (Sheldon & Chalmers, 1994), in particular the prin-
ciples of systematic literature review and meta-analysis. This work has high-
lighted issues such as publication bias, lack of internal and external validity in
many of the studies used to inform policy (Britton et al., 1999), and simply a
shortage of evaluative research.
At the same time, governments have established mechanisms that can draw
on this evidence to decide on what interventions are effective, and in what
circumstances. Most Western European countries now have some form of
technology assessment programme (Banta, 1994), although the situation in
CEE is less well developed and capacity is almost non-existent in most parts of
CIS.
In many cases programmes were established primarily to decide on whether
complex and expensive interventions should be funded, with the primary goal
of containing health care costs. Indeed, in many books, technology assessment
is listed as a means of cost containment, despite the considerable evidence that,
when the appropriate questions are asked, it often uncovers unmet need. How-
ever, the main issue is that discrete interventions, such as a particular type of
scan or a surgical procedure, are only one part of the integrated package of care
that an individual will receive. Fewer technology assessment programmes have
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taken the next step, to look at these entire packages, including both the
interventions and the organization of services to deliver them.
There is, however, a growing volume of research on the effectiveness of
different models of organization. In what can seem like an echo of the past,
when the early work on technology assessment identified wide variations in
outcomes from different interventions, it is now becoming clear that the way in
which services are organized can also be important. For example, the outcome
of treatment of many cancers is better in specialized centres (Karjalainen, 1990;
Kehoe et al., 1994). Hospitals that have supportive organizational cultures
achieve lower inpatient mortality (Aiken et al., 1994). Thirty-day mortality in
AIDS units is lower where there are specialized physicians and a high nurse-to-
patient ratio (Aiken et al., 1999). Yet research findings are often context depend-
ent. For example, trauma centres achieve improved outcomes in the United
States, with its very high level of firearms injuries, but much less so in the
United Kingdom (Nicholl & Turner, 1997). Helicopter ambulances are cost-
effective among the fjords of northern Norway but not in London (Snooks
et al., 1996).
In other cases, differences in outcomes are recognized but inadequately
understood. Cancer survival varies considerably within Europe (Sant et al.,
2001). Some of this variation can be explained by differences in resources but it
is also likely that factors influencing speed of referral and intensity and nature of
treatment play a part. These are largely determined by how cancer care is organ-
ized. Survival of young diabetics is very much higher in the United Kingdom
and Finland than in the United States or Japan, which is also likely to reflect
differences in how care is organized (Matsushima et al., 1997; Laing et al., 1999).
Unfortunately, there is still very little research that can provide the informa-
tion that is needed by purchasers when deciding what type of care they wish to
buy. As this information is a classic public good, it will be underproduced if not
paid for by governments but few governments seem to have made it a priority.
Two rare exceptions are the Institute of Health Services and Policy Research in
the Canadian Institutes of Health Research and the Health Service Delivery
and Organization Programme, within the United Kingdom National Health
Service Research and Development Programme (http://www.lshtm.ac.uk/php/
hsru/sdo/).
While the outputs of research on health care interventions and organizational
structures are an important prerequisite, a further step is necessary to create
models of care. Again there are relatively few examples. An exception is the
series of National Service Frameworks (NSFs) produced by the English National
Institute for Clinical Excellence (http://www.doh.gov.uk/nsf/about.htm). At the
time of writing, eight have been published (and it is planned to produce
approximately one each year, while updating those already prepared): Cancer,
Coronary Heart Disease, Diabetes, Mental Health, Older People, Paediatric
Intensive Care, Renal Services and Children (see Box 7.2).
As well as combining research evidence on both interventions and methods
of service delivery, NSFs take account of existing practice, the potential for, and
likely timescale of change, and the resources required, both in terms of money
and other inputs, such as staff and equipment. They take a broad view of health
improvement, encompassing primary and secondary prevention, diagnosis and
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treatment, and rehabilitation. For example, the coronary heart disease NSF
identifies as immediate priorities the establishment of smoking cessation
clinics, rapid access diagnostic facilities for patients with chest pain, quantified
improvements in the speed of thrombolysis for those with myocardial infarc-
tions, and enhanced use of drugs such as beta-blockers and statins in those
recovering from an infarction.
The NSF model appears to have much strength as a basis for purchasing for
health gain, in particular its breadth of coverage, drawing together the various
elements of care in an integrated fashion and linking aspirations to quantifiable
goals.
A caveat is, however, required. The intrinsic uncertainty in much clinical
practice means that it is unwise to be overprescriptive (McKee & Clarke, 1995). It
is important that this process does not undermine legitimate clinical judgement
and lead to deprofessionalization of health care professionals, with long-term
adverse consequences for the provision of health care.
Finally, it is important to recognize that purchasing can contribute to
population health by encouraging health care providers to place more emphasis
on health promotion. Health care settings offer many opportunities to promote
health (McKee, 1999b). Thus, on average one of every 35 people advised by a
physician to stop smoking will do so, a success rate that is doubled if linked to
use of nicotine replacement therapy. Making health facilities smoke free sends
out a powerful message about the dangers of second-hand smoke. And health
facilities are also major employers, so creation of a healthy environment for
their staff will have wider population benefits.
Consideration of the process of specifying care models raises many questions,
the answers to which are likely to be highly contextual. Who should develop
the evidence? To what extent can evidence developed in one setting be applied
in another? How can this evidence best be incorporated into purchasing? The
existence of these unanswered questions highlights once again the importance
of developing national programmes of research on the organization and delivery
of health care.
Box 7.2 National Health Service Frameworks (United Kingdom)
• Cancer
• Coronary Heart Disease
• Diabetes
• Mental Health
• Older People
• Paediatric Intensive Care
• Renal Services
• Children
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Purchasing care
Having defined the health needs for which care is to be purchased and the
models of care that are sought, the next step is to purchase it. As this activity is
examined in detail in other parts of this book it is not necessary to repeat it here,
although an important issue affecting the ability of purchasers to focus on
health gain is whether they are allowed to contract selectively. Thus, in the
Netherlands, sickness funds must contract with all accredited institutions. In
Germany, contracts for disease management programmes have been developed
within a regional framework, involving negotiations between associations of
sickness funds, physicians and hospitals, that made it impossible to deviate
from rather general conditions and, in particular, to develop contracts that span
different levels in the system, such as inpatient and ambulatory care. Although
such contracts became possible in 2000, they are only now being used. Where
they have been employed, they have, however, made possible a range of
innovative developments, including integrated care pathways. These develop-
ments will be of increasing importance in the future with the growth of chronic
diseases that, coupled with the potential offered by new technology and
research on innovative organizational responses, will demand ever more com-
plex models of care. This will create very considerable challenges for many
existing purchasing arrangements that are often based on an increasingly out-
dated model of care being provided in the framework of an isolated encounter
between an individual patient and an individual physician.
For the present purposes, the key issue is that purchasing, if it is to ensure
optimal health care, and thus maximize health gain, should be embedded
within a broader strategy to ensure availability of high quality inputs. Thus,
there appear to be benefits from having systems where planning, contracting
and capital funding are at least coordinated. Since 1998, the newly created
regional hospital agencies (ARH) in France have assumed much of the responsi-
bility for purchasing previously undertaken by the sickness funds. Their pos-
ition is strengthened as they combine planning, contracting and, for public
hospitals, funding responsibilities. Although experience is still quite limited,
several have shown how they can combine these functions effectively to bring
about changes in the configuration of, and working of, hospitals that align
them much more closely with population health needs (McKee & Healy, 2002).
This model is of particular interest because it is so different from that in many
other countries with funding through social insurance, such as Germany, where
hospital planning and revenue funding are quite separate. It is, however, some-
what similar to the model adopted for the regional health authorities in Italy, in
1999, working within a tax-financed system (Donatini et al., 2001).
The key issue is that purchasing can only work if there is something to pur-
chase, yet the failings of the market are all too apparent. As noted above, many
of the inputs to health services, such as research on effectiveness, are public
goods and will be underproduced in the absence of action by the state or those
acting on its behalf. With some inputs, such as trained staff, the process of
production is long, over 10 years in the case of a specialist physician. Thus, any
signals generated by the market cannot possibly produce an effective response
within a reasonable timeframe. For others, such as health facilities, the return
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on investment available in the cash-limited public sector may be lower than can
be achieved in other sectors, thus leading to underinvestment.
For these and other reasons an ideal strategy will therefore address production
of the major inputs necessary to provide health care: people, facilities and
knowledge. This is clearly a task that goes well beyond purchasers. Governments
have a key role to play, but so do universities, professional associations, industry
and many others.
Yet high quality inputs are not, in themselves, sufficient. Purchasing must
also be embedded in a system to ensure that quality is maintained. Again this
should take account of people, facilities and knowledge. In many cases an indi-
vidual provider will have relationships with multiple purchasers. Consequently
there is a strong case for having national or regional mechanisms that can
ensure that agreed minimum standards are met. Of course, some such mechan-
isms are already ubiquitous, such as the maintenance of a register of physicians,
membership of which implies completion of a specified training programme.
Similarly, pharmaceuticals are everywhere subject to licensing regimes that are
designed to ensure product safety. However, when one goes beyond these uni-
versal systems it becomes clear that there is widespread variation in the
approaches that countries have taken. These have been described in detail by
Scrivens (2002). While there are many terms used to describe these activities,
they can be thought of as falling at different points on two dimensions
(Figure 7.2).
Perhaps the best known review mechanism is the American Joint Commis-
sion on Accreditation of Health-care Organizations (JCAHO), although similar
organizations also exist in Canada and Australia. These models have often
attracted interest in Europe, although this has usually been short-lived or on a
small scale. Thus, from time to time, small groups of hospitals have participated
in a process of accreditation, but on a voluntary basis. In part this is because of
Figure 7.2 Mechanisms to ensure quality.
Source: Scrivens (2002).
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the very different situation in the United States, where there were many small
private hospitals subject to none of the checks and balances that have existed in
more regulated European systems.
The few examples of established accreditation systems in Europe have mostly
arisen in settings where many of the hospitals are privately owned. Thus, in
1987, Belgium introduced a system of certification of hospitals. This had the
immediate effect of reclassifying many small hospitals as nursing homes and so
absolving sickness funds of the requirement to contract with them for hospital
services. In 1996, France established the Agence Nationale d’Accréditation et
d’Evaluation en Santé (ANAES) to develop and implement standards for health
care facilities (ANAES, 1999). The United Kingdom has established the Commis-
sion on Health Improvement, a body that sets standards and combines regular
inspections with publication of measures of performance, such as waiting times
(http:// www.chi.nhs.uk/).
Other countries have rejected the model based on external inspection,
instead requiring health care providers to demonstrate that they are engaged
in internal quality assurance activities. Examples include Germany, in 1991,
and the Netherlands in 1997. The United Kingdom has also adopted this
system, in a series of activities termed ‘clinical governance’, which make con-
tinued registration as a physician contingent on having participated in such
activities. Of course there are many quality assurance activities in other coun-
tries but most involve enthusiastic groups of individuals acting on their own
initiative.
It is not easy to get these mechanisms right, and there are many pitfalls. They
often fall outside the triple agency relationship, as the bodies often depend for
their credibility on being independent of government and purchasers yet they
are required to reflect the priorities of both. This is a difficult balancing act.
While explicit standards have the benefit of promoting consistency they may
also stifle initiative, deflect efforts to meeting measurable standards rather than
less visible, but more important goals, and promote opportunistic behaviour.
Even when failings are identified it may not be clear who is responsible. Is it
the provider management or is it the purchaser, who has provided inadequate
funding? There is also a delicate balance between allocating blame and pro-
viding support to change practices. They are, however, an important element of
strategic purchasing to improve health.
Purchasing need not, of course, be limited to health care. It is also possible to
purchase interventions that are aimed at promoting health by other means.
Thus, in the United Kingdom, some health authorities have purchased smoke
alarms or cycle helmets to be distributed in poorer areas. Clearly, whether this is
appropriate will depend to a considerable extent on the organizational features
of the purchasing structure.
Monitoring outcomes
While appropriate structures and processes are important prerequisites for high
quality care, it is also necessary for strategic purchasers to assure themselves that
the care they are purchasing is leading to optimal outcomes. This task is
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extremely challenging and, at present, there are no perfect solutions. There are
several fundamental problems. One is the difficulty in attributing health out-
comes to specific health interventions. Outcomes reflect not only the technical
quality of care but also the initial condition of the patient, the choices that the
patient makes in relation to his or her treatment and, when small numbers of
events are considered, the play of chance (McKee & Hunter, 1995). A second is
the possibility that a focus on outcomes that are measurable may deflect atten-
tion from others that are less easily identifiable, but perhaps more important for
the patient (Smith, 1995).
So far, attention has focused most on measures of performance based on
routinely collected data, either from existing data systems or, increasingly,
enhanced systems providing additional information on, for example, severity of
illness. Most experience has been obtained from the United States, where sev-
eral states publish the mortality rates achieved by individual hospitals, or in
some cases, by individual surgeons (Hannan et al., 1994).
Clearly the provision of health care involves many different activities, and
some will be more amenable to performance measurement than others. Wilson
has produced a useful framework (Figure 7.3) within which to think about the
potential strategies that can be used for different activities (Wilson, 1991). A
hospital laboratory might be considered as one of his production organizations
where standard output measures are easily quantifiable; although it is important
to be aware that quality may be less easy to measure. However, most of the work
of health care providers will fall into his category of procedural organizations,
which implies that emphasis is likely to be on having clear operating rules and a
strong professional focus. For this reason, monitoring of process measures is
likely to be especially informative. For example, the largest French sickness fund
Figure 7.3 A framework for understanding performance management in the public
sector.
Source: Wilson (1991).
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made imaginative use of process data to study adherence to the guidelines for
care of diabetes, developed by ANAES (Weill et al., 2000). It identified wide-
spread variations in the care provided and, as a consequence, it developed a
programme to improve adherence.
There is now an extensive body of research on the use of performance
measures, not only in the health sector but also in areas such as education, the
environment and policing (Fitz-Gibbon, 1996; Goddard et al., 2000). These
experiences have been described in detail elsewhere. In brief, the key findings
from research on this topic are as follows. First, except in some highly special-
ized areas, such as intensive care, where large amounts of very detailed data are
routinely collected, it is extremely difficult to adjust adequately for differences
in severity of patients, and thus to be certain that observed differences are really
due to variations in quality of care. Second, it is often only possible to know the
outcome of care a long time after that care was given. For example, cancer
survival is typically measured at five years post-treatment, which, allowing for
delays in collecting and processing data, means that data are likely to relate to
care provided at least seven years previously. Third, for many conditions the
number of cases that an individual provider will treat will be few so results will
be subject to considerable random fluctuation. Fourth, publication of perform-
ance measures will often lead to unintended behaviour, such as an aversion to
operate on patients at especially high risk (Green & Wintfeld, 1995). An import-
ant additional caveat in some European countries, such as Germany and Spain,
is that laws on data protection and privacy may preclude the use of some tech-
niques developed elsewhere. Thus, the requirement to obtain consent from
patients whose diseases were recorded by the Hamburg cancer registry reduced
its coverage by 70%, effectively precluding its use for public health purposes
(Verity & Nicoll, 2002).
The implication of this analysis is that monitoring performance by health
care providers in respect of health improvement is extremely complex. It is
likely to involve an iterative approach combining different methods. Thus, con-
cerns raised in analysis of routine data might be investigated further using more
detailed examination of case records or site visits. This, in turn, implies a need
for high-level evaluative skills within purchaser organizations.
The English performance management framework provides an example of
how this might be done (http://www.doh.gov.uk/nhsperformanceindicators/
2002/index.html). Routinely collected data are used to create a series of per-
formance indicators, based on six key issues: fair access, effective delivery of
appropriate care, health improvement, patient/carer experience, efficiency, and
health outcomes. For example, measures of health outcomes include deaths
in hospital following emergency surgery, or following a fractured hip or
myocardial infarction. Unexpected results on these measures should generate
further investigation and the findings are used to inform both the regular
inspections by the Commission for Health Improvement and purchasers during
the contracting process.
The initial choice of measures in England was criticized on a number of
grounds, including the quality of the data used to generate them, the difficulty in
attributing results to aspects of health care, and in some cases the use of compos-
ite indicators whose interpretation is not especially meaningful (McKee &
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Sheldon, 1998). They have, however, undergone a process of refinement, and
while there is little evidence of public interest in them, they do provide an
opportunity to begin to explore otherwise unexplained variations. However,
caution is required. They have also provided a wealth of empirical evidence on
the unintended consequences of performance monitoring (Chapman, 2002). As
the English experience shows, intelligent use of information can be valuable but
an oversimplistic approach is not only useless but frequently harmful.
Screening: a litmus test?
The fundamental arguments underpinning this chapter are that strategic pur-
chasing is necessary because, in its absence, health needs that are not expressed
as demand may not be met and appropriateness of the care provided cannot be
ensured. The examples cited have drawn predominantly on a few countries that
have been especially active in developing the institutional components of a
strategic purchasing policy. However, it is possible that other countries have not
needed to develop these components, as their routine systems are adequate to
identify unmet need and develop integrated care packages. This is a hypothesis
that can easily be tested by looking at population screening. For some types of
screening, such as mammography and cervical screening, there is a consensus
that need exists but it may not always be expressed. In particular, there is con-
siderable evidence that uptake is systematically lower among disadvantaged
populations, even when services are free at the point of use (Sutton et al., 1994).
There is also good evidence that outcomes are better where screening is seen not
as an end in itself but as part of an integrated system of early diagnosis and
treatment, which includes ensuring the quality of all stages of the screening
process as well as mechanisms for referral for further investigation, treatment
and follow-up (Hakama et al., 1985). There is also evidence, for breast screening,
that radiologists who read most films have higher detection rates (Esserman
et al., 2002) and that large screening centres obtain better results than smaller
ones (Blanks et al., 2002), both arguments for organizing specialized pro-
grammes. An ideal purchaser would wish to pay for integrated programmes that
monitored uptake among different groups in the population and provided a
coordinated package of care. For other types of screening, such as routine ultra-
sonography in pregnancy or prostate-specific antigen (PSA) testing, there is
either no evidence of effectiveness or evidence of ineffectiveness. In these cases
an ideal purchaser would not, at present, pay for these interventions.
An important source of information on these issues is a recent volume of the
International Journal of Technology Assessment in Health Care, which brings
together a series of national case studies examining the operation of mammog-
raphy, PSA screening, and ultrasonography in pregnancy in selected Western
European countries. For the present purposes these have been supplemented by
other published papers, including material from the International Breast Cancer
Screening Network (http://appliedresearch.cancer.gov/ibsn/), the European
Network of Reference Centres for Breast Cancer Screening (http://home.
hetnet.nl/%7Emartinth/index.html) as well as by a survey of key informants in
selected countries undertaken to inform this chapter. The case studies confirm
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that there is wide variation between countries (Klabunde et al., 2001). Taking
breast cancer screening (the choice of words is deliberate as mammography is
only one element of a screening programme) as an example, a few countries,
such as the United Kingdom (http://www.doh.gov.uk/public/sb0201.htm),
the Netherlands, Luxembourg (Autier et al., 2002), Iceland (Sigfusson &
Hallgrimsson, 1990) and Finland (Dean & Pamilo, 1999) have managed to
develop integrated policies based on population registers and overseen by qual-
ity assurance systems. Similar local programmes have been implemented, with
varying degrees of success, in some parts of other countries, such as the Flemish
community in Belgium (Vermeulen et al., 2001), the cantons of Geneva, Valais
and Vaud in Switzerland (Faisst et al., 2001), the city of Vienna, and in several
regions of France, Italy, Spain and Sweden. There are, however, only a few pub-
lished evaluations of these subnational programmes and those that exist often
report low levels of uptake (Ganry et al., 1999) and give little information on
other measures such as recall rates or stage at diagnosis.
Where successful, programmes have involved creation of new institutional
entities, which can take various forms. Thus, in the United Kingdom, breast
cancer screening is undertaken within the National Health Service but as a sep-
arately managed programme. It manages the population registers on which
invitations are based (derived from lists of women registered with general prac-
titioners), monitors uptake (and takes action where this is low, either in general
or in particular groups within the population), provides purpose-built screening
centres (both fixed and mobile), and monitors a range of performance measures.
It also maintains close links with other parts of the National Health Service, in
particular surgical facilities and general practitioners, to ensure that the process
of care is integrated.
Other solutions are required in more pluralistic systems. For example, the
Dutch system is based on a network of regional cooperatives involving muni-
cipal public health offices and cancer centres. Luxembourg, which has also
achieved good results within a social insurance system, also established a
separate programme backed up by the refusal by sickness funds to reimburse
screening mammograms outside the screening programme (Autier et al.,
2002).
Elsewhere, however, screening is largely opportunistic. The challenges are
especially great in countries with multiple sickness funds. In these countries,
state health authorities have often taken responsibility for the other common
collective intervention, immunization, as it has proved difficult to achieve high
uptake rates simply by reimbursing private physicians. In Germany, for
example, it is not even possible to obtain timely information on uptake, which
is only obtained at school entry at age six. Immunization is, however, a fairly
straightforward, discrete intervention. The problems are even greater for the
much more complex process of cancer screening, with its requirement for
integration of a population-based element, including monitoring of equity of
uptake, with rapid referral to curative care where appropriate. For example, in
Germany, although large numbers of mammograms are undertaken, the reduc-
tion in breast cancer mortality seen in countries such as the United Kingdom
has not occurred (Figure 7.4). The challenges of implementing such pro-
grammes in countries where purchasers serve populations that are not defined
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by geography are explored in more detail in a companion volume in the
European Observatory series (Saltman et al., 2004).
Taking PSA screening as an example of a test that has not been shown to
be effective, the United Kingdom was the only one where guidance that it
should not be offered has both been produced and been relatively effective. In
conclusion, if the nature of screening activities can be considered a tool to assess
the scope and nature of strategic purchasing in Europe, it would appear that
developments have been extremely uneven.
Conclusions
This chapter suggests a major contradiction between the health system goal to
improve health, set out in the World Health Report 2000 and endorsed by all
European governments, and the reality in most European health systems. The
evidence presented suggests that the third limb of the triple agency relationship
is frequently very limited, at least with regard to improving health. One
response is that we have failed to recognize a vast amount of work that takes
place routinely but, as it is so commonplace, it is not recorded. We dispute this.
In preparation for writing this chapter the initial review of published and
unpublished literature, as well as the relevant sections of the Health Systems in
Transition reports (www.observatory.dk) was supplemented by a detailed ques-
tionnaire that was sent to key informants in most Western European countries
and the conclusions were supported by the participants at the workshop during
which the chapters of this book were discussed.
If we do believe that achieving health gain should be a central goal of health
purchasing, what are the implications? Perhaps the most important one, which
Figure 7.4 Trends in death from breast cancer in selected countries.
158 Purchasing to improve health systems performance
is often overlooked, is that purchasing must take account of the changing
nature of disease and the responses to it. As we have noted above, in many
health systems the organizational and financing structures imply that health
care consists of brief, clearly defined interactions between patients and pro-
viders. A typical example might be an acute respiratory infection or a cataract
extraction. Yet a combination of ageing populations and new therapeutic
opportunities means that an increasingly large volume of health care will be for
chronic disorders, requiring coordinated interventions by different profes-
sionals and specialists over a prolonged period of time. However, many reforms
of health services, such as the introduction of diagnosis-related groups, go in the
opposite direction, seeking to package health care into isolated, homogeneous
interventions. In reality, it is becoming increasingly difficult to define precisely
what the product of health care really is.
The information asymmetry between informed purchasers and providers,
with the former knowing more about unmet need, means that, unless pur-
chasers intervene actively, treatment will often be suboptimal, especially for
those already disadvantaged.
This chapter has identified a series of functions that should take place if
improvements in population health are to be achieved. They are development
of a health strategy, assessment of needs, design of effective packages of inter-
ventions, ensuring that the elements required to deliver these packages are
available, and monitoring outcome. The question is then, who should do these
things? Specifically, which functions fall within the purchasing role, under-
taken by health authorities and sickness funds, and which fall within the stew-
ardship role (see Chapter 8), undertaken by government or agencies acting on
its behalf?
In some cases the answer is relatively clear but for others it will depend on the
context. Effective health strategies combine both technical and political
elements, with the latter including the need for ownership and accountability.
They are an intrinsic part of the concept of stewardship and, as such, will inevit-
ably require a major role by government. Stewardship also includes many of the
elements required to provide a high quality service, such as regulation of profes-
sionals, design standards for facilities, ensuring safety of drugs and equipment,
and the generation of knowledge through targeted research programmes. While
some of these can be delegated to para-state bodies, they remain the responsibil-
ity of governments. Indeed, within the European Union, competition law may
preclude purchasers from developing a regulatory role in some circumstances
(Mossialos & McKee, 2002).
On the other hand, tasks such as assessment of need, negotiation of contracts
for appropriate models of care, and assessment of outcome are more appropri-
ately the rules of purchasers, as they will usually be closer to their populations.
However, a note of caution is required. In countries with multiple social insur-
ance funds it may be difficult to know who the population is, as is illustrated by
the earlier example of screening.
For other functions, such as the definition of packages of care, the most
appropriate location will depend on several circumstances. In many cases there
will be economies of scale so that it will be more efficient for guidance to be
developed nationally or even internationally. While recognizing the need to
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respect national differences, there is considerable scope for shared learning here.
For example, the Spanish Ministry of Health has adapted and translated some of
the English National Service Frameworks.
There is, however, one important message that transcends all of these issues.
It is the need for a major investment in the skills available to governments,
acting as stewards, and purchasing organizations. Health care purchasing is
different from purchasing in many other sectors. The needs are less obvious
and the services purchased are more complex. Furthermore, without active
involvement by purchasers to support coordination by providers, it is unlikely
that the services required will be available for purchase. This means that both
governments and purchasers must enhance their skills in the many disciplines
that fall within the remit of public health and health service research. It seems
likely that it is the relative lack of this expertise that will be the main constraint
on the development of effective strategic purchasing in many countries.
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